Introduction
Angiogenesis occurs with the imbalance between positive and negative factors that keep angiogenesis. Under certain conditions such as hypoxia or inflammation that activate angiogenic factors, the balance may shift to angiogenesis (Folkman, 2006) . Stimulation of endothelial cells with angiogenic factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) induce endothelial cells to produce and export a plethora of proteases, such as matrix metalloproteases and plasminogen activators to digest the basement membrane and to allow endothelial cells to invade the surrounding tissue. Endothelial cells proliferate and migrate to form a sprout (Risau, 2003) . Pathological angiogenesis in the eye is the most common cause of blindness in all age groups (Aiello et al., 1994) . Particularly, age-related macular degeneration (AMD) is the leading cause of blindness over the age of 55 years in developed countries (Klein et al., 1995) .
Although the detailed mechanism was not elucidated as yet, choroidal neovascularization (CNV) leads to severe vision loss in patients of AMD (Macular Photocoagulation Group, 1991) . CNV invades the subretinal space by the vessel proliferation from the choroidal vessels following the rupture of Bruch's membrane.
The new vessels are fragile and leaky inducing hemorrhages or exudation damaging to photoreceptor cell function. On the other hand, these proliferating vessels induce the formation of fibrovascular scar, which result in the irreversible damage to the retinal function and likely blindness (Gehrs et al., 2006) . Since excessive proliferation of vascular cells is the essential mechanism of CNV, it is This article has not been copyedited and formatted. The final version may differ from this version. (Miller et al., 1986) .
Rotenoids, compounds from the flavonoid family, have chemo-preventive activity by inhibiting NADH:ubiquinone oxidoreductase activity and by suppressing steadystate mRNA levels and enzymatic activity of 12-O-tetradecanoylphorbol 13-acetateinduced ODC (Gerhäuser et al., 1995; Fang and Casida, 1998) . The rotenoid, deguelin, was found in several plant species, including Mundulea sericea (Leguminosae) (Gerhäuser et al., 1997) . We have demonstrated that deguelin inhibits cyclooxygenase-2 expression and phosphatidylinositol 3-kinase (PI3K)/Aktmediated signaling pathways and that contributes to its anti-proliferative effects (Chun et al., 2003; Lee, 2004; Lee et al., 2004; Lee et al., 2005) . However, we also found that deguelin reduced the expression of Hsp90-binding proteins, including HIF-1α protein and induced the degradation of HIF-1α protein independent of the reactive oxygen species and PI3K-Akt pathways (Oh et al., 2007) .
In the present study, we demonstrate that deguelin inhibits in vitro angiogenesis of human umbilical vein endothelial cells (HUVECs) and in vivo angiogenesis of CAM without cytotoxic effect, and significantly reduces laser-induced CNV in a mouse model of AMD without significant retinal toxicity. In addition to the antiproliferative activity of deguelin to cancer cells (Chun et al., 2003; Lee, 2004; Lee et al., 2004; Lee et al., 2005; Oh et al., 2007) , we herein suggest that deguelin, a 
Cell culture
HUVECs were maintained in a gelatin-coated dish at 37 in a humidified atmosphere of 5 % CO2/95 % air in M199 medium with 20 % fetal bovin serum, 100 units/ml penicillin, 100 g/ml streptomycin, 3ng/ml basic fibroblast growth factor and 1ml heparin. HUVECs used in this study were taken from passages 6 to 7.
Preparation of Deguelin
Deguelin was manufactured from the natural product rotenone (Sigma-Aldrich, Milwaukee, WI, USA) via four steps, as previously described (Anzenveno, 1979).
The final product was more than 98 % pure. Deguelin was stored at a stock concentration of 1mM in a nitrogen tank.
Cell viability assay
Cell viability was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5- for 48 hrs. The medium was then replaced with fresh medium containing 0.5 mg/ml
MTT for 4 h. After incubation, the medium was carefully removed from the plate and DMSO was added to solubilize formazan produced from MTT by the viable cells. Absorbance was measured at 540nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay
Deguelin was intravitreously injected to 7-to 8-week-old female C57BL/6J mice.
The mice were sacrificed at 3 days after 0.1 µ M deguelin injection, and eyes were enucleated. Enucleated globes were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 24 h, and embedded in paraffin. TUNEL staining was performed with a kit (ApopTag Fluorescein Green; Intergen, Purchase, NY, USA), according to the manufacturer's instructions. TUNEL-positive cells were evaluated in randomly selected fields at ×400 magnification viewed under fluorescein microscopy (BX50, OLYMPUS, Japan).
Tube formation assay
Tube formation was assayed as described previously (Min et al., 2007) . HUVECs To assess the anti-angiogenic activity of deguelin, the mice were injected intravitreously with 0.1 µM deguelin in 1µl PBS on the tenth day after laser photocoagulation, when maximum CNV began. These experiments were repeated at least 25 times.
Qualitative assessment of CNV by fluorescein angiography
At 14 days after laser photocoagulation, deeply anesthetized mice were perfused through the tail vein with high molecular weight (MW=500,000) fluorescein conjugated dextran (Sigma-Aldrich Ltd., St. Louis, MO, USA) dissolved in PBS.
After 1 h perfusion, the eyes were enucleated and fixed in 4% paraformaldehyde for 4 hours. The eyeballs were dissected, flat-mounted in Dako mounting medium There were at least 25 animals in each group.
Statistical Analysis
Statistical differences between groups were evaluated with the Student unpaired t-test (two-tailed). Mean ± SD is shown. P 0.05 was considered significant.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results

Effect of deguelin on the viability of HUVECs
To investigate cytotoxic effect of deguelin on HUVECs, MTT assay was carried out in various concentrations of deguelin (0~10µM). The viability of HUVECs was not affected up to 1 µM deguelin (Figure 1 ). 0.1µM deguelin, effective therapeutic concentration to inhibit VEGF expression in our previous report (Oh et al., 2007) , did not affect the viability of HUVECs.
Retinal toxicity of deguelin
Retinal toxicity to intravitreal injection of 1 
Effect of deguelin on tube formation of HUVECs
To investigate the effect of deguelin on the angiogenic phenotype of tube formation in vitro assay, VEGF was used as an angiogenic factor. VEGF induced JPET#132720
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Discussion
We have demonstrated that deguelin has anti-proliferative activity to cancer cells via regulation of cyclooxygenase-2 expression and phosphatidylinositol 3-kinase (PI3K)/Akt-mediated signaling pathways (Chun et al., 2003; Lee, 2004; Lee et al., 2004; Lee et al., 2005) . Recently, we also found out that deguelin reduces VEGF expression through the destabilization of HIF-1α protein. Interestingly, this antiangiogenic activity of deguelin was independent on reactive oxygen species and PI3K-Akt pathways (Oh et al., 2007) .
Because deguelin is derived from rotenone, which can inhibit NADH: ubiquinone oxidoreductase in mitochondrial oxidative phosphorylation (Fang and Casida, 1998) , it is possible that deguelin induces side effects in cardiovascular, respiratory, and nervous system. However, we never observed major toxicity in the mice at the therapeutically effective dose (Lee et al., 2005; Oh et al., 2007) . In terms of the mechanism of action deguelin may be different from that of rotenone to inhibit tubulin polymerization (Marshall and Himes, 1978; Srivastava and Panda, 2007) , which could be one reason that deguelin is safer. However, it is also possible that the reason of no grave toxicity in deguelin may be in degree, which means that deguelin may be a weaker inhibitor. In this study, deguelin showed no effect on the viability of HUVEC cells and no retinal toxicity up to 1µM which is equivalent to 10 times of effective dose (0.1 µM) to CNV.
The blood vessel growth in CNV correlates with the expression of VEGF, bFGF, and their receptors (Edelman and Castro, 2000) . At the concentration to effectively Given the well-documented anti-proliferative effect on HUVECs and antiangiogenic effect on CAM and CNV in the present study, we suggest that deguelin could be a new anti-angiogenic agent to CNV, which is from rotenone. Furthermore, deguelin may be also applied to other vaso-proliferative retiniopathies such as ROP and diabetic retinopathy. 
